A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 121, Issue , 2016, Pages 39-47

  Ding, Zhen ^a   Li, Xiu ^a   Lu, Youjin ^a   Rong, Guangsheng ^b   Yang, Ruiqing ^c   Zhang, Ruixia ^d   Wang, Guiqin ^e   Wei, Xiqiang ^f   Ye, Yongqing ^g   Qian, Zhaoxia ^h   Liu, Hongyan ^a   Zhu, Daifeng ^b   Zhou, Ruiqing ^c   Zhu, Kun ^d   Ni, Rongping ^e   Xia, Kui ^f   Luo, Nan ^g   Pei, Cong ⁱ  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Hefei Second People's Hospital   (China)

^c Chaoyang Hospital   (China)

^d Dongfang Hospital   (China)

^e Fuyang People's Hospital   (China)

^f Huaibei 1st People's Hospital   (China)

^g Lu'an 1st People's Hospital   (China)

^h Bengbu First People's Hospital   (China)

ⁱ Hefei Binhu Hospital   (China)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Inhaled corticosteroid; Systemic corticosteroid

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; BUDESONIDE; CREATININE; GLUCOSE; LEVOFLOXACIN; METHYLPREDNISOLONE; QUINOLONE DERIVATIVE; CARBON DIOXIDE; GLUCOCORTICOID; OXYGEN;

ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ADULT; AGED; ARTERIAL GAS; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD GAS ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE ASSESSMENT TEST; CLINICAL OUTCOME; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INCIDENCE; INFUSION PUMP; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL NEBULIZER; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXYGEN TENSION; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE ASSESSMENT; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SYMPTOM ASSESSMENT; ACUTE DISEASE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PARTIAL PRESSURE; PATHOPHYSIOLOGY; VITAL CAPACITY;

ACUTE DISEASE; ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; BUDESONIDE; CARBON DIOXIDE; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OXYGEN; PARTIAL PRESSURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SINGLE-BLIND METHOD; VITAL CAPACITY;

EID: 84993981366     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.10.013     Document Type: Article

References (37)

1. [1] Global Initiative for Chronic Obstructive Lung Diseases, Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 21 June 2016 http://www.goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/.
2. [2] Ai-Ping, C., Lee, K.H., Lim, T.K., In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest 128 (2005), 518–524.
3. [3] Soler-Cataluna, J.J., Martinez-Garcia, M.A., Roman Sanchez, P., Salcedo, E., Navarro, M., Ochando, R., Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (2005), 925–931.
4. [4] Ambrosino, N., Simonds, A., The clinical management in extremely severe COPD. Respir. Med. 101 (2007), 1613–1624.
5. [5] Schmidt, S.A., Johansen, M.B., Olsen, M., Xu, X., Parker, J.M., Molfino, N.A., et al. The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study. BMJ Open, 4, 2014, e006720.
6. [6] Dixit, D., Bridgeman, M.B., Andrews, L.B., Narayanan, N., Radbel, J., Parikh, A., et al. Acute exacerbations of chronic obstructive pulmonary disease: diagnosis, management, and prevention in critically ill patients. Pharmacotherapy 35 (2015), 631–648.
7. [7] National Clinical Guideline Centres, National Institute for Health and Clinical Excellence: Guidance, August 2014 http://www.nice.org.uk/guidance/CG101,2010.
8. [8] Davies, L., Angus, R.M., Calverley, P.M., Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354 (1999), 456–460.
9. [9] Niewoehner, D.E., Erbland, M.L., Deupree, R.H., Collins, D., Gross, N.J., Light, R.W., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N. Engl. J. Med. 340 (1999), 1941–1947.
10. [10] Ferrari, M., Manea, L., Anton, K., Bruzzone, P., Meneghello, M., Zamboni, F., et al. Anemia and hemoglobin serum levels are associated with exercise capacity and quality of life in chronic obstructive pulmonary disease. BMC Pulm. Med., 15, 2015, 58.
11. [11] Sethi, S., Murphy, T.F., Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359 (2008), 2355–2365.
12. [12] Shaykhiev, R., Crystal, R.G., Innate immunity and chronic obstructive pulmonary disease: a mini-review. Gerontology 59 (2013), 481–489.
13. [13] Hanania, N.A., Sharma, G., Sharafkhaneh, A., COPD in the elderly patient. Semin. Respir. Crit. Care Med. 31 (2010), 596–606.
14. [14] Misof, B.M., Moreira, C.A., Klaushofer, K., Roschger, P., Skeletal implications of chronic obstructive pulmonary disease. Curr. Osteoporos. Rep. 14 (2016), 49–53.
15. [15] Tin, S.S., Wiwanitkita, V., Osteoporosis in chronic obstructive pulmonary disease. Lung India, 32, 2015, 200.
16. [16] Kiyokawa, H., Muro, S., Oguma, T., Sato, S., Tanabe, N., Takahashi, T., et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. COPD 9 (2012), 235–242.
17. [17] FitzGerald, J.M., Shragge, D., Haddon, J., Jennings, B., Lee, J., Bai, T., et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can. Respir. J. 7 (2000), 61–67.
18. [18] Tricco, A.C., Strifler, L., Veroniki, A.A., Yazdi, F., Khan, P.A., Scott, A., et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open, 5, 2015, e009183.
19. [19] Sun, X., He, Z., Zhang, J., Deng, J., Bai, J., Li, M., et al. Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. Pulm. Pharmacol. Ther. 31 (2015), 111–116.
20. [20] Montuschi, P., Pharmacological treatment of chronic obstructive pulmonary disease. Int. J. Chronic Obstr. Pulm. Dis. 1 (2006), 409–423.
21. [21] Barnes, P.J., How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br. J. Pharmacol. 148 (2006), 245–254.
22. [22] Lahelma, S., Kirjavainen, M., Kela, M., Herttuainen, J., Vahteristo, M., Silvasti, M., et al. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br. J. Clin. Pharmacol. 59 (2005), 167–173.
23. [23] Pilcher, J., Weatherall, M., Perrin, K., Beasley, R., Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 9 (2015), 287–293.
24. [24] Parola, D., Romani, S., Petroianni, A., Locorriere, L., Terzano, C., Treatment of acute exacerbations with non-invasive ventilation in chronic hypercapnic COPD patients with pulmonary hypertension. Eur. Rev. Med. Pharmacol. Sci. 16 (2012), 183–191.
25. [25] Luo, Q., Zheng, Z., Cen, H., Jiang, M., Chen, Q., A modified nebulization modality versus classical ultrasonic nebulization and oxygen-driven nebulization in facilitating airway clearance in patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. J. Thorac. Dis. 7 (2015), 1130–1141.
26. [26] Fraser, J.F., Spooner, A.J., Dunster, K.R., Anstey, C.M., Corley, A., Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax 71 (2016), 759–761.
27. [27] Criner, G.J., Bourbeau, J., Diekemper, R.L., Ouellette, D.R., Goodridge, D., Hernandez, P., et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 147 (2015), 894–942.
28. [28] Hwang, J.L., Weiss, R.E., Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab. Res. Rev. 30 (2014), 96–102.
29. [29] Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E.D., Leigh, R., et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin. Immunol., 9, 2013, 30.
30. [30] Burt, M.G., Willenberg, V.M., Petersons, C.J., Smith, M.D., Ahern, M.J., Stranks, S.N., Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford) 51 (2012), 1112–1119.
31. [31] Tamez Perez, H.E., Gomez de Ossio, M.D., Quintanilla Flores, D.L., Hernandez Coria, M.I., Tamez Pena, A.L., Cuz Perez, G.J., et al. Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses. Rev. Assoc. Med. Bras. 58 (2012), 125–128.
32. [32] Cai, B.Q., Cai, S.X., Chen, R.C., Cui, L.Y., Feng, Y.L., Gu, Y.T., et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. Int. J. Chronic Obstr. Pulm. Dis. 9 (2014), 381–395.
33. [33] Dilger, K., Halter, J., Bertz, H., Lopez-Lazaro, L., Gratwohl, A., Finke, J., Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Biol. Blood Marrow Transpl. 15 (2009), 336–343.
34. [34] Shrewsbury, S.B., Bosco, A.P., Uster, P.S., Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int. J. Pharm. 365 (2009), 12–17.
35. [35] Szefler, S.J., Eigen, H., Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J. Allergy Clin. Immunol. 109 (2002), 730–742.
36. [36] Pearlman, D.S., Preclinical properties of budesonide: translation to the clinical setting. Clin. Ther. 25:Suppl. C (2003), C75–C91.
37. [37] Kunitomi, T., Hashiguchi, M., Mochizuki, M., Effect of common comparators in indirect comparison analysis of the effectiveness of different inhaled corticosteroids in the treatment of asthma. PLoS One, 10, 2015, e0120836.